Web Desc
Fibrosis: From Bench to Bedside
Organizer(s): Jeremy S. Duffield, Steven R. Ledbetter and John P. Iredale
Date: March 23 - 28, 2014
Location: Keystone Resort, Keystone, CO, USA
Sponsored by Gilead Sciences, Inc., InterMune, Inc., MedImmune, Shire Human Genetic Therapies and Takeda Pharmaceutical Company Limited
Summary of Meeting:
Fibrosis of all the internal organs is increasingly recognized as a deleterious and ominous consequence of, normal aging, repetitive subclinical tissue injury or severe persistent tissue injury. Fibrosis is increasingly seen as the next broad-ranging target for therapeutics after Cancer, and there is now a rush to first-in-class therapeutics. The primary cell that lays down fibrotic tissue is the myofibroblast. Until very recently, the biology of myofibroblasts is relatively undeveloped due to a lack of definitive markers, and lack of clear ontogeny. This meeting: 1) Brings together biotech, pharma and academia in a seamless meeting. 2) Focuses on fibrosis as an abnormal wound healing or tissue repair response identifying aberrant developmental pathways, and progenitor cell responses. c) Has a broad focus on basic biology of myofibroblasts, their progenitors, progenitor ontogeny, and their interaction with the immune system in disease. d) Focuses on fibrosis as a normal part of aging and the epigenetics involved in maintaining myofibroblasts in an activated state. e) Includes a full session on biomarkers; among the major blocks to progress is the lack of biomarkers. f) Feature formal presentations from biotech/pharma on the most promising new therapeutics in development or clinical trial. All of these highlighted areas are underdeveloped and are rapidly changing. The Keystone Symposia Fibrosis meeting is intended to be the premier international meeting for anyone with an interest in this disease process. The meeting brings together academics from a broad range of interest areas, including cancer, vascular biology, stem cell biology and tissue regeneration, as well as those with organ specific-interests.
Scholarship Deadline: November 20 2013
Discounted Abstract Deadline: November 20 2013
Abstract Deadline: December 18 2013
Discounted Registration Deadline: January 21 2014
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Gilead Sciences, Inc.InterMune, Inc.MedImmuneShire Human Genetic TherapiesTakeda Pharmaceutical Company Limited
We gratefully acknowledge additional support for this conference from:
Genkyotex SAMyriad-RBMPromedior, Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Promedior, Inc.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, March 23 | 4:00PM - 8:00PM
Arrival and Registration
Room: Longs Peak Foyer


Sunday, March 23 | 6:00PM - 8:00PM
Welcome Mixer
Room: Longs Peak Foyer


Monday, March 24 | 7:00AM - 8:00AM
Breakfast
Room: Shavano/Torreys


Monday, March 24 | 8:00AM - 8:15AM
Introduction
Room: Longs/Grays Peaks

Speaker 1 of 1
Jeremy S. Duffield, Vertex Pharmaceuticals, USA

Monday, March 24 | 8:15AM - 9:15AM
Keynote Address
Room: Longs/Grays Peaks

Speaker 1 of 3
* Jeremy S. Duffield, Vertex Pharmaceuticals, USA

Monday, March 24 | 8:15AM - 9:15AM
Keynote Address
Room: Longs/Grays Peaks

Speaker 2 of 3
* Steven R. Ledbetter, Genzyme Corporation, USA

Monday, March 24 | 8:15AM - 9:15AM
Keynote Address
Room: Longs/Grays Peaks

Speaker 3 of 3
Harry (Hal) C. Dietz, Johns Hopkins University School of Medicine, Blade Therapeutics, USA
Insights Regarding the Pathogenesis and Treatment of Scleroderma

Monday, March 24 | 9:15AM - 12:00PM
Senescence, Cell Stress and the Fibrogenic Response
Room: Longs/Grays Peaks

Speaker 1 of 8
* Erwin P. Böttinger, Hasso-Plattner-Institut für Digital Engineering GmbH, Germany

Monday, March 24 | 9:15AM - 12:00PM
Senescence, Cell Stress and the Fibrogenic Response
Room: Longs/Grays Peaks

Speaker 2 of 8
* Steven R. Ledbetter, Genzyme Corporation, USA

Monday, March 24 | 9:15AM - 12:00PM
Senescence, Cell Stress and the Fibrogenic Response
Room: Longs/Grays Peaks

Speaker 3 of 8
Judith Campisi, Buck Institute for Research on Aging, USA
The Role of Cellular Senescence in Inflammation and Fibrosis

Monday, March 24 | 9:15AM - 12:00PM
Senescence, Cell Stress and the Fibrogenic Response
Room: Longs/Grays Peaks

Speaker 4 of 8
Dean Sheppard, University of California, San Francisco, USA
Fibroblast alphav Integrins as Therapeutic Targets in Tissue Fibrosis

Monday, March 24 | 9:15AM - 12:00PM
Senescence, Cell Stress and the Fibrogenic Response
Room: Longs/Grays Peaks

Speaker 5 of 8
John P. Iredale, University of Bristol, UK
Macrophages and Resolution of Liver Fibrosis

Monday, March 24 | 9:15AM - 12:00PM
Senescence, Cell Stress and the Fibrogenic Response
Room: Longs/Grays Peaks

Speaker 6 of 8
David Lagares, Massachusetts General Hospital, USA
Short Talk: “Fibronucleation” and Stiffness Gradients Drive Tissue Fibrosis by Promoting Fibroblast Recruitment and Activation through Cell “Durotaxis”

Monday, March 24 | 9:15AM - 12:00PM
Senescence, Cell Stress and the Fibrogenic Response
Room: Longs/Grays Peaks

Speaker 7 of 8
Massimiliano Mellone, University of Southampton, UK
Short Talk: Fibroblast to Myofibroblast Differentiation in Fibrosis and Tumor Microenvironment: Role of DNA Damage Response (DDR) Pathway

Monday, March 24 | 9:15AM - 12:00PM
Senescence, Cell Stress and the Fibrogenic Response
Room: Longs/Grays Peaks

Speaker 8 of 8
Neetu Razdan, Rutgers University, USA
Short Talk: Telomere Dysfunction Is a Mediator of Myofibroblast Transdifferentiation

Monday, March 24 | 9:55AM - 10:15AM
Coffee Break
Room: Longs Peak Foyer


Monday, March 24 | 12:00PM - 1:00PM
Poster Setup
Room: Shavano/Torreys


Monday, March 24 | 12:00PM - 5:00PM
On Own for Lunch and Recreation


Monday, March 24 | 1:00PM - 10:00PM
Poster Viewing
Room: Shavano/Torreys


Monday, March 24 | 4:30PM - 5:00PM
Coffee Available
Room: Longs Peak Foyer


Monday, March 24 | 5:00PM - 7:15PM
Metabolic Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 1 of 7
* Thomas A. Wynn, Pfizer, USA

Monday, March 24 | 5:00PM - 7:15PM
Metabolic Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 2 of 7
* John Varga, Feinberg School of Medicine, USA

Monday, March 24 | 5:00PM - 7:15PM
Metabolic Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 3 of 7
Rik Derynck, University of California, San Francisco, USA
Control of Epithelial-Mesenchymal Transition by TGF-beta Receptor Presentation

Monday, March 24 | 5:00PM - 7:15PM
Metabolic Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 4 of 7
Erwin P. Böttinger, Hasso-Plattner-Institut für Digital Engineering GmbH, Germany
Mitochondrial Dysfunction and Renal Fibrogenesis

Monday, March 24 | 5:00PM - 7:15PM
Metabolic Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 5 of 7
Nelson Chau, LogicBio Therapeutics, USA
Oligonucleotide-Mediated Antagonism of Dysregulated MicroRNAs Represents a Novel Therapeutic Strategy for Treatment of Fibrosis

Monday, March 24 | 5:00PM - 7:15PM
Metabolic Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 6 of 7
Benjamin Korman, Northwestern University, USA
Short Talk: Adipocyte-Specific Ablation of PPAR-gamma Co-Repressor NCoR Modulates Metabolism and Attenuates Experimental Skin Fibrosis

Monday, March 24 | 5:00PM - 7:15PM
Metabolic Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 7 of 7
Monique Bernard, University of Montreal Hospital Centre - Research Centre, CRCHUM, Canada
Short Talk: mTORC2 Links Autophagy and Myofibroblast Differentiation

Monday, March 24 | 7:15PM - 8:15PM
Social Hour with Lite Bites
Room: Shavano/Torreys


Monday, March 24 | 7:30PM - 10:00PM
Poster Session 1:
1A Fate Mapping Studies
1B Metabolic

/Stress/Senescence Pathways
1C Scleroderma/Systemic Sclerosis
1D New Insights from Screens
1E Reprogramming/Epigenetics
1F MicroRNA
1G Perivasculature

Room: Shavano/Torreys

Speaker 1 of 3
* David A. Brenner, University of California, San Diego, USA

Monday, March 24 | 7:30PM - 10:00PM
Poster Session 1:
1A Fate Mapping Studies
1B Metabolic

/Stress/Senescence Pathways
1C Scleroderma/Systemic Sclerosis
1D New Insights from Screens
1E Reprogramming/Epigenetics
1F MicroRNA
1G Perivasculature

Room: Shavano/Torreys

Speaker 2 of 3
* Jelena Mann, Newcastle University, UK

Monday, March 24 | 7:30PM - 10:00PM
Poster Session 1:
1A Fate Mapping Studies
1B Metabolic

/Stress/Senescence Pathways
1C Scleroderma/Systemic Sclerosis
1D New Insights from Screens
1E Reprogramming/Epigenetics
1F MicroRNA
1G Perivasculature

Room: Shavano/Torreys

Speaker 3 of 3
* Boris Hinz, University of Toronto, Canada

Tuesday, March 25 | 7:00AM - 8:00AM
Breakfast
Room: Shavano/Torreys


Tuesday, March 25 | 8:00AM - 11:45AM
Perivascular and Other Mesenchymal Lineages - Bipolar Cells
in Disease and Fibrogenesis

Room: Longs/Grays Peaks

Speaker 1 of 8
* Andrew M. Tager, Massachusetts General Hospital, USA

Tuesday, March 25 | 8:00AM - 11:45AM
Perivascular and Other Mesenchymal Lineages - Bipolar Cells
in Disease and Fibrogenesis

Room: Longs/Grays Peaks

Speaker 2 of 8
Jeremy S. Duffield, Vertex Pharmaceuticals, USA
Mechanisms of Perivascular Cell Activation in Disease

Tuesday, March 25 | 8:00AM - 11:45AM
Perivascular and Other Mesenchymal Lineages - Bipolar Cells
in Disease and Fibrogenesis

Room: Longs/Grays Peaks

Speaker 3 of 8
Lucie Peduto, Institut Pasteur, France
The Fate and Function of ADAM12(+) Perivascular Cells in Injury and Fibrosis

Tuesday, March 25 | 8:00AM - 11:45AM
Perivascular and Other Mesenchymal Lineages - Bipolar Cells
in Disease and Fibrogenesis

Room: Longs/Grays Peaks

Speaker 4 of 8
Christian Göritz, Karolinska Institutet, Sweden
The Role of Pericytes in Central Nervous System Scarring and Fibrosis

Tuesday, March 25 | 8:00AM - 11:45AM
Perivascular and Other Mesenchymal Lineages - Bipolar Cells
in Disease and Fibrogenesis

Room: Longs/Grays Peaks

Speaker 5 of 8
Jonathan M. Graff, University of Texas Southwestern Medical Center, USA
Adipose Stem Cells: Give me a Pill and not a Treadmill

Tuesday, March 25 | 8:00AM - 11:45AM
Perivascular and Other Mesenchymal Lineages - Bipolar Cells
in Disease and Fibrogenesis

Room: Longs/Grays Peaks

Speaker 6 of 8
Ingmar Mederacke, Columbia University, USA
Short Talk: Fate Tracing Reveals Hepatic Stellate Cells as Main Contributors to the Myofibroblast Pool in Toxic, Biliary and Fatty Liver Disease

Tuesday, March 25 | 8:00AM - 11:45AM
Perivascular and Other Mesenchymal Lineages - Bipolar Cells
in Disease and Fibrogenesis

Room: Longs/Grays Peaks

Speaker 7 of 8
Tien Peng, University of Pennsylvania, USA
Short Talk: Hedgehog Regulates Fibroblast Proliferation during Normal Tissue Homeostasis and Fibrotic Repair

Tuesday, March 25 | 8:00AM - 11:45AM
Perivascular and Other Mesenchymal Lineages - Bipolar Cells
in Disease and Fibrogenesis

Room: Longs/Grays Peaks

Speaker 8 of 8
* Andrew Leask, University of Saskatoon, Canada
Short Talk: Skin Progenitor Cells Contribute to Bleomycin-Induced Skin Fibrosis

Tuesday, March 25 | 9:20AM - 9:40AM
Coffee Break
Room: Longs Peak Foyer


Tuesday, March 25 | 11:45AM - 1:00PM
Poster Setup
Room: Shavano/Torreys


Tuesday, March 25 | 11:45AM - 2:30PM
On Own for Lunch and Recreation


Tuesday, March 25 | 1:00PM - 10:00PM
Poster Viewing
Room: Shavano/Torreys


Tuesday, March 25 | 2:30PM - 4:30PM
Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea
?
Room: Longs/Grays Peaks

Speaker 1 of 9
* Heather A. Arnett, NuMedii, Inc., USA

Tuesday, March 25 | 2:30PM - 4:30PM
Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea
?
Room: Longs/Grays Peaks

Speaker 2 of 9
* Kamran Atabai, University of California, San Francisco, USA

Tuesday, March 25 | 2:30PM - 4:30PM
Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea
?
Room: Longs/Grays Peaks

Speaker 3 of 9
Martin L. Decaris, Pliant Therapeutics, USA
Proteomic Quantitation of Altered Extracellular Matrix Protein Turnover in Animal Models of Pulmonary Fibrosis

Tuesday, March 25 | 2:30PM - 4:30PM
Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea
?
Room: Longs/Grays Peaks

Speaker 4 of 9
Terrie-Anne Cock, Pharmaxis, Australia
Inhibition of TGF-beta Signaling and LOXL2: Pharmaxis’ Dual Small Molecule Approach to Treat Fibrosis

Tuesday, March 25 | 2:30PM - 4:30PM
Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea
?
Room: Longs/Grays Peaks

Speaker 5 of 9
Ming-Hui Fan, University of Pittsburgh, USA
Fibroblast Activation Protein (FAP), An Endogenous Regulator of Fibrosis, Participates in Collagen Catabolism

Tuesday, March 25 | 2:30PM - 4:30PM
Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea
?
Room: Longs/Grays Peaks

Speaker 6 of 9
Thomas H. Barker, Georgia Institute of Technology, USA
A CD90/Fyn/alphavbeta3 Integrin Mechanosignaling Axis Modulates ECM Rigidity Sensing in Lung Fibrosis

Tuesday, March 25 | 2:30PM - 4:30PM
Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea
?
Room: Longs/Grays Peaks

Speaker 7 of 9
Franco Klingberg, University of Toronto, Canada
Organized Is More Efficient: Pre-Stress in the ECM Enhances Activation of Latent TGF-beta1 by Myofibroblast Contraction

Tuesday, March 25 | 2:30PM - 4:30PM
Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea
?
Room: Longs/Grays Peaks

Speaker 8 of 9
Peter D. Mariner, University of Colorado, USA
Dynamic Hydrogel Platform for Studying the Effects of Environmental Stiffness on Myofibroblast Activation

Tuesday, March 25 | 2:30PM - 4:30PM
Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea
?
Room: Longs/Grays Peaks

Speaker 9 of 9
Nathan Sandbo, University of Wisconsin, USA
Myofibroblasts Exhibit Elevated Fibronectin Assembly that Is Intrinsic to its Contractile Phenotype

Tuesday, March 25 | 2:30PM - 4:30PM
Workshop 1B: How Best to Regulate Myofibroblast Activation
Room: Quandary Peak

Speaker 1 of 9
* Harry (Hal) C. Dietz, Johns Hopkins University School of Medicine, Blade Therapeutics, USA

Tuesday, March 25 | 2:30PM - 4:30PM
Workshop 1B: How Best to Regulate Myofibroblast Activation
Room: Quandary Peak

Speaker 2 of 9
* Tatiana Kisseleva, University of California, San Diego, USA

Tuesday, March 25 | 2:30PM - 4:30PM
Workshop 1B: How Best to Regulate Myofibroblast Activation
Room: Quandary Peak

Speaker 3 of 9
Sergei P. Atamas, University of Maryland School of Medicine, USA
Deciphering Mechanisms of IL-33-Driven Fibrosis

Tuesday, March 25 | 2:30PM - 4:30PM
Workshop 1B: How Best to Regulate Myofibroblast Activation
Room: Quandary Peak

Speaker 4 of 9
Christian Beyer, University of Erlangen-Nuremberg, Germany
The Soluble Guanylate Cyclase (sGC) Inhibits Fibrosis by Interfering with Non-Canonical TGFbeta-Signaling

Tuesday, March 25 | 2:30PM - 4:30PM
Workshop 1B: How Best to Regulate Myofibroblast Activation
Room: Quandary Peak

Speaker 5 of 9
Michael P. Czubryt, University of Manitoba, Canada
Regulation of Myocardial Fibrogenesis and Fibroblast Phenotype by Scleraxis

Tuesday, March 25 | 2:30PM - 4:30PM
Workshop 1B: How Best to Regulate Myofibroblast Activation
Room: Quandary Peak

Speaker 6 of 9
Emily Hamburg, Case Western Reserve University, USA
Cell Autonomous Mechanisms of Fibrosis Due to Elevated beta-Catenin Activity in Dermal Fibroblasts

Tuesday, March 25 | 2:30PM - 4:30PM
Workshop 1B: How Best to Regulate Myofibroblast Activation
Room: Quandary Peak

Speaker 7 of 9
Alison E. John, University of Nottingham, UK
Alveolar TGF-beta Activation and Lung Homeostasis Is Regulated by Epithelial Gq/G11 Signaling

Tuesday, March 25 | 2:30PM - 4:30PM
Workshop 1B: How Best to Regulate Myofibroblast Activation
Room: Quandary Peak

Speaker 8 of 9
Katherine M. Martin, University of Manchester, UK
Integrin Beta1 Regulates Hepatic Stellate Cell Activation

Tuesday, March 25 | 2:30PM - 4:30PM
Workshop 1B: How Best to Regulate Myofibroblast Activation
Room: Quandary Peak

Speaker 9 of 9
Saimir Luli, Newcastle University, UK
A Novel Liposomal Technology to Selectively Target Hepatic Myofibroblasts

Tuesday, March 25 | 4:30PM - 5:00PM
Coffee Available
Room: Longs Peak Foyer


Tuesday, March 25 | 5:00PM - 7:15PM
Innate and Adaptive Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 1 of 7
* John P. Iredale, University of Bristol, UK

Tuesday, March 25 | 5:00PM - 7:15PM
Innate and Adaptive Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 2 of 7
* Timothy Radstake, University Medical Center Utrecht, Netherlands

Tuesday, March 25 | 5:00PM - 7:15PM
Innate and Adaptive Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 3 of 7
Paul Kubes, University of Calgary, Canada
Intravascular Immunity in the Development and Resolution of Sterile Injury

Tuesday, March 25 | 5:00PM - 7:15PM
Innate and Adaptive Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 4 of 7
Thomas A. Wynn, Pfizer, USA
Macrophage Subsets in Type-2-Dependent Fibrosis

Tuesday, March 25 | 5:00PM - 7:15PM
Innate and Adaptive Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 5 of 7
Scott L. Friedman, Icahn School of Medicine at Mount Sinai, USA
Autophagy Fuels Mesenchymal Cell Fibrogenesis in Liver and Other Tissues


Tuesday, March 25 | 5:00PM - 7:15PM
Innate and Adaptive Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 6 of 7
Brigid M. O'Flaherty, Emory University, USA
Short Talk: Evaluating the Role of MHV68 M1 Induced Vbeta4+CD8+ T Cell Expansion in Development of Pulmonary Fibrosis

Tuesday, March 25 | 5:00PM - 7:15PM
Innate and Adaptive Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 7 of 7
Christian Stockmann, University of Zurich, Switzerland
Short Talk: Sinusoidal Remodeling by Myeloid Cell-Derived VEGF Is Required for the Resolution of Liver Fibrosis

Tuesday, March 25 | 7:15PM - 8:15PM
Social Hour with Lite Bites
Room: Shavano/Torreys


Tuesday, March 25 | 7:30PM - 10:00PM
Poster Session 2:
2A Infectious Mechanisms
2B New Targ

ets
2C Innate/Adaptive Immunity
2D Underrepresented Organs/Diseases
2E Repair/Regeneration

Room: Shavano/Torreys

Speaker 1 of 3
* Lynn M. Schnapp, University of Wisconsin-Madison, USA

Tuesday, March 25 | 7:30PM - 10:00PM
Poster Session 2:
2A Infectious Mechanisms
2B New Targ

ets
2C Innate/Adaptive Immunity
2D Underrepresented Organs/Diseases
2E Repair/Regeneration

Room: Shavano/Torreys

Speaker 2 of 3
* Paul Kubes, University of Calgary, Canada

Tuesday, March 25 | 7:30PM - 10:00PM
Poster Session 2:
2A Infectious Mechanisms
2B New Targ

ets
2C Innate/Adaptive Immunity
2D Underrepresented Organs/Diseases
2E Repair/Regeneration

Room: Shavano/Torreys

Speaker 3 of 3
* Paul W. Noble, Cedars-Sinai Medical Center, USA

Wednesday, March 26 | 7:00AM - 8:00AM
Breakfast
Room: Shavano/Torreys


Wednesday, March 26 | 8:00AM - 11:45AM
Established and Promising Therapies Entering Clinical Develo
pment

Room: Longs/Grays Peaks

Speaker 1 of 11
* Dean Sheppard, University of California, San Francisco, USA

Wednesday, March 26 | 8:00AM - 11:45AM
Established and Promising Therapies Entering Clinical Develo
pment

Room: Longs/Grays Peaks

Speaker 2 of 11
* Mark L. Lupher, Jr., Muregen, LLC, USA

Wednesday, March 26 | 8:00AM - 11:45AM
Established and Promising Therapies Entering Clinical Develo
pment

Room: Longs/Grays Peaks

Speaker 3 of 11
Paul W. Noble, Cedars-Sinai Medical Center, USA
Update on Clinical Trials in Idiopathic Pulmonary Fibrosis

Wednesday, March 26 | 8:00AM - 11:45AM
Established and Promising Therapies Entering Clinical Develo
pment

Room: Longs/Grays Peaks

Speaker 4 of 11
Naftali Kaminski, Yale University School of Medicine, USA
MicroRNAs in Lung Fibrosis

Wednesday, March 26 | 8:00AM - 11:45AM
Established and Promising Therapies Entering Clinical Develo
pment

Room: Longs/Grays Peaks

Speaker 5 of 11
Elizabeth G. Trehu, Jounce Therapeutics, USA
and

Wednesday, March 26 | 8:00AM - 11:45AM
Established and Promising Therapies Entering Clinical Develo
pment

Room: Longs/Grays Peaks

Speaker 6 of 11
Bernt van den Blink, Erasmus MC, Netherlands
PRM-151 in Idiopathic Pulmonary Fibrosis and Myelofibrosis

Wednesday, March 26 | 8:00AM - 11:45AM
Established and Promising Therapies Entering Clinical Develo
pment

Room: Longs/Grays Peaks

Speaker 7 of 11
Andrew M. Tager, Massachusetts General Hospital, USA
Lysophosphatidic Acid (LPA)-LPA1 Signaling in Fibrogenesis

Wednesday, March 26 | 8:00AM - 11:45AM
Established and Promising Therapies Entering Clinical Develo
pment

Room: Longs/Grays Peaks

Speaker 8 of 11
Jeffrey R. Crosby, Ionis Pharmaceuticals, Inc., USA
Short Talk: Inhaled Antisense Oligonucleotides for the Treatment of Pulmonary Fibrosis: The Role of Osteopontin in Mouse Models of Disease

Wednesday, March 26 | 8:00AM - 11:45AM
Established and Promising Therapies Entering Clinical Develo
pment

Room: Longs/Grays Peaks

Speaker 9 of 11
Cédric Szyndralewiez, Genkyotex, Switzerland
Short Talk: The NADPH Oxidase (NOX) Inhibitor GKT137831 Alleviates Liver Inflammation and Fibrosis in a Mouse Model of Non-Alcoholic Steatohepatitis (NASH)

Wednesday, March 26 | 8:00AM - 11:45AM
Established and Promising Therapies Entering Clinical Develo
pment

Room: Longs/Grays Peaks

Speaker 10 of 11
Timothy Radstake, University Medical Center Utrecht, Netherlands
Short Talk: The Chemokine CXCL4 Is a Novel biomarker in Systemic Sclerosis Linking Inflammation, Endothelial Dysfunction and Fibrosis

Wednesday, March 26 | 8:00AM - 11:45AM
Established and Promising Therapies Entering Clinical Develo
pment

Room: Longs/Grays Peaks

Speaker 11 of 11
Mushriq Al-Jazrawe, University of Toronto, Canada
Short Talk: Preventing Fibrosis by Targeting beta-Catenin: A Preclinical Study of Topical Nefopam

Wednesday, March 26 | 9:20AM - 9:40AM
Coffee Break
Room: Longs Peak Foyer


Wednesday, March 26 | 11:45AM - 1:00PM
Poster Setup
Room: Shavano/Torreys


Wednesday, March 26 | 11:45AM - 5:00PM
On Own for Lunch and Recreation


Wednesday, March 26 | 1:00PM - 10:00PM
Poster Viewing
Room: Shavano/Torreys


Wednesday, March 26 | 4:30PM - 5:00PM
Coffee Available
Room: Longs Peak Foyer


Wednesday, March 26 | 5:00PM - 7:15PM
Promising New Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 1 of 7
* Paul W. Noble, Cedars-Sinai Medical Center, USA

Wednesday, March 26 | 5:00PM - 7:15PM
Promising New Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 2 of 7
* Victoria Smith, Gilead Sciences, USA

Wednesday, March 26 | 5:00PM - 7:15PM
Promising New Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 3 of 7
Heather A. Arnett, NuMedii, Inc., USA
Identifying Novel Myofibroblast Pathways in IPF Lungs

Wednesday, March 26 | 5:00PM - 7:15PM
Promising New Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 4 of 7
Robert Lafyatis, University of Pittsburgh Medical Center, USA
Anti-TGF-beta/Fresolimumab Inhibition of Skin Fibrosis and TGF-beta-Regulated Biomarker Gene Expression in Patients with Systemic Sclerosis

Wednesday, March 26 | 5:00PM - 7:15PM
Promising New Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 5 of 7
Greg R. Dressler, University of Michigan, USA
Novel TGF-beta Superfamily Regulators in Renal Fibrosis

Wednesday, March 26 | 5:00PM - 7:15PM
Promising New Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 6 of 7
James P. Pritchett, University of Manchester, UK
Short Talk: A Role for Mechano-Transduction via Yap/Taz in Hepatic Stellate Cell Activation

Wednesday, March 26 | 5:00PM - 7:15PM
Promising New Pathways in Fibrogenesis
Room: Longs/Grays Peaks

Speaker 7 of 7
Cristi L. Galindo, Vanderbilt University, USA
Short Talk: Neuregulin Inhibits Cardiac Fibrosis and Mediates Anti-Fibrotic Signaling in Cardiac Fibroblasts

Wednesday, March 26 | 7:15PM - 8:15PM
Social Hour with Lite Bites
Room: Shavano/Torreys


Wednesday, March 26 | 7:30PM - 10:00PM
Poster Session 3:
3A Clinical Trials
3B Biomarkers/Mon

itoring/Devices
3C New Models
3D Signaling
3E Matrix Signaling to Cells

Room: Shavano/Torreys

Speaker 1 of 3
* Bruno Péault, University of California, Los Angeles, USA

Wednesday, March 26 | 7:30PM - 10:00PM
Poster Session 3:
3A Clinical Trials
3B Biomarkers/Mon

itoring/Devices
3C New Models
3D Signaling
3E Matrix Signaling to Cells

Room: Shavano/Torreys

Speaker 2 of 3
* Stuart J. Forbes, University of Edinburgh, UK

Wednesday, March 26 | 7:30PM - 10:00PM
Poster Session 3:
3A Clinical Trials
3B Biomarkers/Mon

itoring/Devices
3C New Models
3D Signaling
3E Matrix Signaling to Cells

Room: Shavano/Torreys

Speaker 3 of 3
* Andrew M. Tager, Massachusetts General Hospital, USA

Thursday, March 27 | 7:00AM - 8:00AM
Breakfast
Room: Shavano/Torreys


Thursday, March 27 | 8:00AM - 11:45AM
Resolution of Fibrosis and Pathways of Repair and Regenerati
on

Room: Longs/Grays Peaks

Speaker 1 of 10
* Jeremy S. Duffield, Vertex Pharmaceuticals, USA

Thursday, March 27 | 8:00AM - 11:45AM
Resolution of Fibrosis and Pathways of Repair and Regenerati
on

Room: Longs/Grays Peaks

Speaker 2 of 10
* Tien Peng, University of Pennsylvania, USA

Thursday, March 27 | 8:00AM - 11:45AM
Resolution of Fibrosis and Pathways of Repair and Regenerati
on

Room: Longs/Grays Peaks

Speaker 3 of 10
Bruno Péault, University of California, Los Angeles, USA
Role of Vascular Pericytes in Normal and Pathologic Tissue Regeneration

Thursday, March 27 | 8:00AM - 11:45AM
Resolution of Fibrosis and Pathways of Repair and Regenerati
on

Room: Longs/Grays Peaks

Speaker 4 of 10
Gabrielle Kardon, University of Utah, USA
Interactions between Muscle Stem Cells, Fibroblasts and Macrophages Are Critical for Muscle Regeneration

Thursday, March 27 | 8:00AM - 11:45AM
Resolution of Fibrosis and Pathways of Repair and Regenerati
on

Room: Longs/Grays Peaks

Speaker 5 of 10
Stuart J. Forbes, University of Edinburgh, UK
Liver Regeneration

Thursday, March 27 | 8:00AM - 11:45AM
Resolution of Fibrosis and Pathways of Repair and Regenerati
on

Room: Longs/Grays Peaks

Speaker 6 of 10
Michelle D. Tallquist, University of Hawaii, USA
Cardiac Resident Mesenchymal Cells in Organogensis and Fibrosis

Thursday, March 27 | 8:00AM - 11:45AM
Resolution of Fibrosis and Pathways of Repair and Regenerati
on

Room: Longs/Grays Peaks

Speaker 7 of 10
Dario R. Lemos, University of British Columbia, Canada
Short Talk: The Innate Immune Response Modulates Fibrosis during Skeletal Muscle Regeneration via TNF-alpha/TGF-beta Signaling on Mesenchymal Multipotent Cells

Thursday, March 27 | 8:00AM - 11:45AM
Resolution of Fibrosis and Pathways of Repair and Regenerati
on

Room: Longs/Grays Peaks

Speaker 8 of 10
Laura Johnson, University of Michigan, USA
Short Talk: Intestinal Organoids: A Model of Intestinal Fibrosis

Thursday, March 27 | 8:00AM - 11:45AM
Resolution of Fibrosis and Pathways of Repair and Regenerati
on

Room: Longs/Grays Peaks

Speaker 9 of 10
Wilder Scott, University of British Columbia, Canada
Short Talk: Analysis of Mesenchymal Stromal Cell Fate in Tissue Regeneration

Thursday, March 27 | 8:00AM - 11:45AM
Resolution of Fibrosis and Pathways of Repair and Regenerati
on

Room: Longs/Grays Peaks

Speaker 10 of 10
Norihiko Takeda, University of Tokyo, Japan
Short Talk: Roles of Macrophages Hypoxia Signaling in Cardiac Fibrosis

Thursday, March 27 | 9:20AM - 9:40AM
Coffee Break
Room: Longs Peak Foyer


Thursday, March 27 | 11:45AM - 2:30PM
On Own for Lunch and Recreation


Thursday, March 27 | 2:30PM - 4:30PM
Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers
and Devices
Room: Quandary Peak

Speaker 1 of 10
* Scott L. Friedman, Icahn School of Medicine at Mount Sinai, USA

Thursday, March 27 | 2:30PM - 4:30PM
Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers
and Devices
Room: Quandary Peak

Speaker 2 of 10
Edford Sinkala, University Teaching Hospital, Zambia
High Concentration of Fibrotic and Inflammatory Markers among Patients with Schistosomal Liver Diseases

Thursday, March 27 | 2:30PM - 4:30PM
Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers
and Devices
Room: Quandary Peak

Speaker 3 of 10
Scott M. Turner, Pliant Therapeutics, USA
Identification of a Putative Serum Protein Biomarker for Noninvasive Measurement of Fibrogenesis: Correlation with Hepatic Collagen Synthesis and Histological Score in Humans

Thursday, March 27 | 2:30PM - 4:30PM
Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers
and Devices
Room: Quandary Peak

Speaker 4 of 10
John A. Baugh, University College Dublin, Ireland
Serum Amyloid P-Component: A Novel Biomarker and Potential Treatment for Left Ventricular Remodelling and Heart Failure

Thursday, March 27 | 2:30PM - 4:30PM
Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers
and Devices
Room: Quandary Peak

Speaker 5 of 10
Thomas H. Barker, Georgia Institute of Technology, USA
A New Modality for Imaging Fibrosis - Detection of an Extracellular Integrin “Switch” A Conformation Specific Antibody against Fibronectin for Imaging of Fibrosis

Thursday, March 27 | 2:30PM - 4:30PM
Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers
and Devices
Room: Quandary Peak

Speaker 6 of 10
Florin L. Craciun, Brigham & Women's Hospital/ Harvard Medical School, USA
Discovery of 12 New Candidate Biomarkers for Chronic Kidney Disease: From Mouse Models to Human Patients

Thursday, March 27 | 2:30PM - 4:30PM
Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers
and Devices
Room: Quandary Peak

Speaker 7 of 10
Claire Emson, Genentech, Inc., USA
Collagen Synthesis Rate Distinguishes between Early and Late Diffuse Scleroderma Subjects

Thursday, March 27 | 2:30PM - 4:30PM
Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers
and Devices
Room: Quandary Peak

Speaker 8 of 10
Jose D. Herazo-Maya, Yale University, USA
A 52 Peripheral Blood Gene Signature Predicts Poor Outcome and Disease Progression in Idiopathic Pulmonary Fibrosis

Thursday, March 27 | 2:30PM - 4:30PM
Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers
and Devices
Room: Quandary Peak

Speaker 9 of 10
Mette Juul Nielsen, Nordic Bioscience, Denmark
Serological Markers of Extracellular Matrix Remodeling Enables Early Diagnosis and Predicts Fibrosis Progression of Chronic Hepatitis C

Thursday, March 27 | 2:30PM - 4:30PM
Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers
and Devices
Room: Quandary Peak

Speaker 10 of 10
Karl Kossen, Blade Therapeutics, USA
Plasma MMP-7 Predicts Mortality in Idiopathic Pulmonary Fibrosis

Thursday, March 27 | 2:30PM - 4:30PM
Workshop 2B: New Pathways/Drugs from SCREENS
Room: Longs/Grays Peaks

Speaker 1 of 9
* Linda C. Burkly, Biogen, Inc., USA

Thursday, March 27 | 2:30PM - 4:30PM
Workshop 2B: New Pathways/Drugs from SCREENS
Room: Longs/Grays Peaks

Speaker 2 of 9
* Stuart J. Forbes, University of Edinburgh, UK

Thursday, March 27 | 2:30PM - 4:30PM
Workshop 2B: New Pathways/Drugs from SCREENS
Room: Longs/Grays Peaks

Speaker 3 of 9
David Zhang, Mount Sinai School of Medicine, USA
A Genomics Strategy Highlights Hand2 Regulation in Hepatic Stellate Cell Activation

Thursday, March 27 | 2:30PM - 4:30PM
Workshop 2B: New Pathways/Drugs from SCREENS
Room: Longs/Grays Peaks

Speaker 4 of 9
Kamran Atabai, University of California, San Francisco, USA
Functional Genomic Screen Identifies Novel Mediators of Collagen Uptake and Turnover

Thursday, March 27 | 2:30PM - 4:30PM
Workshop 2B: New Pathways/Drugs from SCREENS
Room: Longs/Grays Peaks

Speaker 5 of 9
Xavier Espanel, NovAliX Belgique, France
Development and Automation of a Fibrotic Phenotypic Screening Using a High Content Screening Approach

Thursday, March 27 | 2:30PM - 4:30PM
Workshop 2B: New Pathways/Drugs from SCREENS
Room: Longs/Grays Peaks

Speaker 6 of 9
David W. Griggs, St. Louis University, USA
Preclinical Development of Multi-Functional Integrin Antagonists for Treatment of Organ Fibrosis

Thursday, March 27 | 2:30PM - 4:30PM
Workshop 2B: New Pathways/Drugs from SCREENS
Room: Longs/Grays Peaks

Speaker 7 of 9
John B. Nicholas, InterMune, Inc., USA
Phenotypic Screening for Inhibitors of Fibroblast to Myofibroblast Transition (FMT)

Thursday, March 27 | 2:30PM - 4:30PM
Workshop 2B: New Pathways/Drugs from SCREENS
Room: Longs/Grays Peaks

Speaker 8 of 9
Kevin K. Kim, University of Michigan, USA
Overexpression of Id2 Transcription Factor Promotes Alveolar Epithelial Cell Proliferation and Attenuates Belomycin-Induced Pulmonary Fibrosis

Thursday, March 27 | 2:30PM - 4:30PM
Workshop 2B: New Pathways/Drugs from SCREENS
Room: Longs/Grays Peaks

Speaker 9 of 9
Branko Stefanovic, Florida State University, USA
Discovery and Validation of a Potent Antifibrotic Drug with Unique Mechanism of Action

Thursday, March 27 | 4:30PM - 5:00PM
Coffee Available
Room: Longs Peak Foyer


Thursday, March 27 | 5:00PM - 7:00PM
Myofibroblast Reprogramming
Room: Longs/Grays Peaks

Speaker 1 of 6
* Michelle D. Tallquist, University of Hawaii, USA

Thursday, March 27 | 5:00PM - 7:00PM
Myofibroblast Reprogramming
Room: Longs/Grays Peaks

Speaker 2 of 6
* Naftali Kaminski, Yale University School of Medicine, USA

Thursday, March 27 | 5:00PM - 7:00PM
Myofibroblast Reprogramming
Room: Longs/Grays Peaks

Speaker 3 of 6
David A. Brenner, University of California, San Diego, USA
Myofibroblast Inactivation in the Resolution of Fibrosis

Thursday, March 27 | 5:00PM - 7:00PM
Myofibroblast Reprogramming
Room: Longs/Grays Peaks

Speaker 4 of 6
Jelena Mann, Newcastle University, UK
Epigenetics in Myofibroblast Reprogramming

Thursday, March 27 | 5:00PM - 7:00PM
Myofibroblast Reprogramming
Room: Longs/Grays Peaks

Speaker 5 of 6
Boris Hinz, University of Toronto, Canada
The Effect of the Mechanical Environment on Myofibroblast Development and Persistence

Thursday, March 27 | 5:00PM - 7:00PM
Myofibroblast Reprogramming
Room: Longs/Grays Peaks

Speaker 6 of 6
Eleni Stylianou, Lerner Research Institute, Cleveland Clinic, USA
Short Talk: Defining the Fibrotic DNA Methylome in Crohn’s Disease

Thursday, March 27 | 7:00PM - 7:10PM
Concluding Remarks

Speaker 1 of 1
Jeremy S. Duffield, Vertex Pharmaceuticals, USA

Thursday, March 27 | 7:10PM - 8:10PM
Social Hour with Lite Bites
Room: Shavano/Torreys


Thursday, March 27 | 8:00PM - 11:00PM
Entertainment
Room: Shavano/Torreys


Thursday, March 27 | 8:00PM - 11:00PM
Cash Bar
Room: Shavano/Torreys


Friday, March 28 | 10:25AM - 10:25AM
Departure


*Session Chair.